Results of Immunochemotherapy with Interleukin-2, Interferon-&amp;alpha;&lt;sub&gt;2&lt;/sub&gt; and 5-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer

Samland, Dirk; Reiher, F.; Schmidt, Uwe; Gruss, A.; Allhoff, E. P.

doi:10.1159/000019847

Cited by 17 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 However, the amount of patients with long-term complete remissions remains low and is found in about 4 to 15%. 6,7,15 In our analysis of 35 patients treated with this triple drug therapy, the rate of objective remissions was 34.3% with a 1-and 3-year-survival rate of 76 and 32% and therefore comparable with the above mentioned studies. Variations of the triple drug regimen resulting in quite similar or controversial results have been reported in other series.…”

Section: Discussionsupporting

confidence: 88%

“…With this therapeutic strategy, objective remissions of ranging from 18 to 39% with a median survival of up to 24 months have been reported. 4,5,7,15 Recently, the analysis of a German trial comparing IL-2, IFN-a2a, and 5-FU versus tamoxifen revealed a 5-year survival rate of 25% for the chemoimmunotherapy arm. 5 However, the amount of patients with long-term complete remissions remains low and is found in about 4 to 15%.…”

Section: Discussionmentioning

confidence: 99%

“…4,5 Several encouraging studies have shown response rates between 19 and 40% with a reported 5-year survival rate of 25%, respectively. 5,6,7,8 Recently, first clinical studies have been performed combining cytokines such as IL-2 and IFN-a2a with 13-cis-retinoic acid (13-CRA). 9,10,11 13-CRA is not effective as a single agent in mRCC but has been shown to enhance the antiproliferative effects of IFN-a2a in vitro.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of 13-cis-Retinoic Acid on Chemoimmunotherapy of Metastatic Renal Cell Carcinoma—Results of a Retrospective Analysis

Roigas

Değer

Taymoorian³

et al. 2003

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Chemoimmunotherapy (CIT) with interleukin-2, interferon-alpha2a, and 5-fluorouracil is an accepted treatment option of metastatic renal cell carcinoma (mRCC). Because of the enhancement of the antiproliferative effects of interferon-alpha2a, 13-cis-retinoic acid (13-CRA) might be of potential usefulness for immunotherapy. We have investigated the effect of 13-CRA in patients treated with chemoimmunotherapy. Seventy-two patients with mRCC and a Karnofsky performance index > or = 80% were retrospectively analyzed. Thirty-six patients received chemoimmunotherapy and 36 other patients were treated similarly but with addition of daily 60 mg 13-CRA. Response was assessed according to the UICC criteria. Survival was calculated by Kaplan Meier estimation and compared with the log-rank test. In the CIT group objective remissions occurred in 34.3% (95% CI 19.1-52.2) and stabilizations in 42.9% (median follow-up 16 months). In the CIT plus 13-CRA group, objective remissions were seen in 26.4% (95% CI 12.9-44.4) and stabilizations in 50% (median follow-up 17 months). One- and three-year survival rates were 76% and 32% in the CIT group and 82% and 37% in the CIT plus 13-CRA group. The combination of CIT and 13-CRA did not significantly differ in objective remissions and estimated survival compared with CIT. Our retrospective data suggest that 13-CRA does not enhance the therapeutic efficacy of CIT in mRCC patients with a good performance status.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of 13-cis-Retinoic Acid on Chemoimmunotherapy of Metastatic Renal Cell Carcinoma—Results of a Retrospective Analysis

Roigas

Değer

Taymoorian³

et al. 2003

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Similar results have been reported in two studies of thirty‐four and fifty‐five patients 20,21 . However, other groups have demonstrated less impressive response rates, with objective responses reported between 2 and 19% 6,22–28 . There are several factors that may have influenced such discrepancies.…”

Section: Discussionmentioning

confidence: 82%

Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

Marx

Taylor

Goldstein

2005

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Interleukin-2 (IL-2) and interferon-α (IFN-α ) have been shown to have antitumor activity in MRCC and the addition of 5-FU has increased the effect of this combination. 7,8 To improve the results, a number of schedules combining the two cytokines with chemotherapy were developed, however, the combination produces high toxicity and high dose IL-2 requires hospitalization of the patient. 9 In vitro and in vivo studies suggest synergistic antitumor activity against renal cell cancer of IL-2 and IFN-α and use of combination reduces the dose of IL-2 and limits the toxicity.…”

Section: Introductionmentioning

confidence: 99%

Outpatient 5‐fluorouracil +α‐interferon + interleukin‐2 chemoimmunotherapy in metastatic renal cell cancer patients

Özkan

Altınbaş

et al. 2005

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Background : Renal cell carcinoma is the most common malignancy of the kidney in adults. The treatment of metastatic disease remains a particularly difficult problem given the resistance of this disease to most treatment options and usually requires hospitalization. This prospective study aimed to determine the efficacy and systemic toxicity of outpatient Chemoimmunotherapy (CIT) in metastatic renal cell cancer (MRCC) patients. Methods : The patients with MRCC received a combination of 5-fluorouracil 400 mg/m 2 intravenously on day 1 once a week, interferon-α 10 MU on days 1,3,5 during weeks 1 and 3, interleukin-2 18 MU on days 1,3,5 during weeks 2 and 4 subcutaneously. Results : Twenty-three MRCC patients were enrolled into the study. The performance status was ECOG 0-2. The median age was 60 years. Twenty patients were evaluable. Chemoimmunotherapy was administered for a median of 10 weeks (range 2-32). Partial remission was obtained in two patients, stable disease in five and no complete response was detected. Median overall survival (OAS) was 10.0 months (95% CI 5.5-14.5 months), progression-free survival (PFS) 7.0 months (95% CI 5.1-8.9 months). The 1-year OAS and PFS rate was 27% and 7%, respectively. Median OAS for patients with and without nephrectomy was 10.0 months (95%CI 7.2-12.8 months) and 6.0 months (95%CI 1.4-10.5 months), median PFS 7.0 months (95% CI 4.1-9.9 months) and 5.0 months (95% CI 3.7-6.2 months), respectively, and there was no statistical significant difference ( P = 0.27 and P = 0.20). Most common complaints were fatigue, fever and nausea. Grade 3-4 side-effects were not observed. Conclusion : This CIT scheme showed a low objective response rate, but when combined with stable disease, clinical benefit is favorable. Outpatient administration with mild toxicity is advantageous.

show abstract

Results of Immunochemotherapy with Interleukin-2, Interferon-α<sub>2</sub> and 5-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer

Cited by 17 publications

References 18 publications

Effects of 13-cis-Retinoic Acid on Chemoimmunotherapy of Metastatic Renal Cell Carcinoma—Results of a Retrospective Analysis

Effects of 13-cis-Retinoic Acid on Chemoimmunotherapy of Metastatic Renal Cell Carcinoma—Results of a Retrospective Analysis

Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

Outpatient 5‐fluorouracil +α‐interferon + interleukin‐2 chemoimmunotherapy in metastatic renal cell cancer patients

Contact Info

Product

Resources

About